Wu Ping, Davies Faith E, Horton Clive, Jenner Matthew W, Krishnan Biju, Alvares Caroline L, Saso Radovan, McCormack Rita, Dines Sharon, Treleaven Jennifer G, Potter Michael N, Ethell Mark E, Morgan Gareth J
Haemato-Oncology Unit, Royal Marsden Hosptial, Sutton, Surrey, UK.
Leuk Lymphoma. 2006 Nov;47(11):2335-8. doi: 10.1080/10428190600821955.
A retrospective case-matched study was conducted to compare the oral regimen CTD (cyclophosphamide - thalidomide - dexamethasone) and infusional CVAMP (cyclophosphamide - vincristine - doxorubicin - methylprednisolone) as induction therapy followed by autologous peripheral blood stem-cell transplantation (PBSCT) for newly diagnosed multiple myeloma patients. The response rate after three cycles of treatment was statistically higher with CTD (n = 27) compared to CVAMP (n = 27) (89% vs. 56%, P = 0.016). Toxicity studies showed more neutropenia (grade 3/4) (4% vs. 60%, P = 0.0002) with CVAMP and more thrombotic episodes with CTD (11% vs. 4%). CTD may emerge as the superior induction regimen prior to PBSCT, in terms of high efficacy and better tolerability.
开展了一项回顾性病例匹配研究，以比较口服方案CTD（环磷酰胺-沙利度胺-地塞米松）和静脉输注方案CVAMP（环磷酰胺-长春新碱-阿霉素-甲基泼尼松龙）作为新诊断的多发性骨髓瘤患者的诱导治疗方案，并随后进行自体外周血干细胞移植（PBSCT）。与CVAMP组（n = 27）相比，CTD组（n = 27）在三个治疗周期后的缓解率在统计学上更高（89% 对56%，P = 0.016）。毒性研究显示，CVAMP组有更多的中性粒细胞减少（3/4级）（4% 对60%，P = 0.0002），而CTD组有更多的血栓形成事件（11% 对4%）。就高疗效和更好的耐受性而言，CTD可能成为PBSCT前更优的诱导方案。
